bromocriptine tablet
pharmel inc - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists
bromocriptine capsule
pharmel inc - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists
cycloset- bromocriptine mesylate tablet
santarus, inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 0.8 mg - cycloset is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use - cycloset should not be used to treat type 1 diabetes or diabetic ketoacidosis. - limited efficacy data in combination with thiazolidinediones. - efficacy has not been confirmed in combination with insulin. cycloset is contraindicated in: - patients with known hypersensitivity to bromocriptine, ergot-related drugs, or any of the excipients in cycloset. - patients with syncopal migraine. bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. loss of consciousness during a migraine may reflect dopamine receptor hypersensitivity. cycloset is a dopamine receptor agonist and may, therefore, potentiate the risk for syncope in these patients. - postpartum patients. serious and life-threatening adverse reactions have been reported with bromocriptine use in this population [see warnings and precautions (5.7), adverse reactions
medocriptine tablets 2.5mg
medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - bromocriptine mesilate - tablet - bromocriptine mesilate 2.5 mg - anti-parkinson drugs
parlodel bromocriptine 10mg (as mesilate) capsule bottle
sandoz pty ltd - bromocriptine mesilate, quantity: 11.5 mg (equivalent: bromocriptine, qty 10 mg) - capsule, hard - excipient ingredients: lactose monohydrate; gelatin; maize starch; colloidal anhydrous silica; magnesium stearate; maleic acid; titanium dioxide - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con
aspen bromocriptine 2,5 mg
pharmacare limited - bromocriptine mesylate - tablet - each tablet contains bromocriptine mesylate equivalent to bromocriptine 2,5 mg
parlodel
novartis new zealand ltd - bromocriptine mesilate 11.48mg - capsule - 10 mg - active: bromocriptine mesilate 11.48mg excipient: gelatin magnesium stearate
co bromocriptine capsules 5mg
cobalt pharmaceuticals company - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists
co bromocriptine tablets 2.5mg
cobalt pharmaceuticals company - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists
aa pharma bromocriptine tablet 2.5 mg
pharmaforte singapore pte ltd - bromocriptine mesylate eqv bromocriptine - tablet, film coated - 2.5 mg - bromocriptine mesylate eqv bromocriptine 2.5 mg